Vanda Pharmaceuticals

VNDA

時価総額 $2.44億

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on Wednesday shared an update regarding its clinical development pipeline.

Vanda Pharmaceuticals said on Wednesday its experimental drug for social anxiety disorder ​failed the main goal of a ‌late-stage study, prompting the company to put the program on hold pending further analysis of ​the data.

Phase III clinical study of VQW-765 in adults with social anxiety disorder did not meet its primary endpoint Consistent with prior studies, VQW-765 was safe and well tolerated WASHINGTON, Oct. 14, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an update on its clinical development program for VQW-765, a novel small molecule alpha 7 nicotinic acetylcholine receptor (α7-nAChR) partial agonist. Vanda's Phase III clinical study, VP-VQW-765-3201 (Study 3201), which evaluated VQW-765 for the on-demand treatment of acute anxiety in adults with social anxiety disorder, did not meet its primary endpoint.

WASHINGTON, Oct. 2, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced participation at the European Academy of Dermatology and Venereology (EADV) Annual Meeting, being held in Vienna, Austria, from September 30 through October 3, 2026. The following will be presented: Presentation Title: "Rapid reduction in neutrophils and neutrophil percentage-to-albumin ratio upon treatment with imsidolimab in patients with GPP" Abstract ID: AS-4323 Poster Number: P1769 Presentation Title: "Immunogenicity of Imsidolimab for the Treatment of Generalized Pustular Psoriasis (GPP)" Abstract ID: AS-2420 Poster Number: P1784 Presentation Title: "Imsidolimab Improves Generalized Pustular Psoriasis (GPP) Pustulation as Measured by the Pustulation Rating Scale (PRS): Results from the GEMINI-1 Study" Abstract ID: AS-2421 Poster Number: P2806 About Imsidolimab Imsidolimab is a fully humanized IgG4 monoclonal antibody that inhibits IL-36 receptor signaling and is being developed for GPP, a rare orphan indication.

Study met its primary endpoint: timing of sleep onset shifted 37.1 minutes earlier versus placebo (p=0.022) 60% of HETLIOZ ® treated participants shifted sleep at least 30 minutes earlier, compared to 15% of the placebo arm WASHINGTON, Sept. 29, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced positive topline results from its pivotal Phase III study of HETLIOZ® (tasimelteon) 20 mg in adults with Delayed Sleep-Wake Phase Disorder (DSWPD).

WASHINGTON, Sept. 2, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate at the following upcoming investor conferences in September 2026: The Wells Fargo 21st Annual Healthcare Conference in Boston on Tuesday, September 8, 2026.

WASHINGTON, Aug. 24, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that its investigational drug imsidolimab has received Orphan Designation from the European Commission, based on the positive opinion received from the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP), for the treatment of Generalized Pustular Psoriasis (GPP), which is a severe, chronic, and potentially life-threatening inflammatory skin disease driven by dysregulation in the interleukin-36 (IL-36) signaling pathway.1 The US Food and Drug Administration (FDA) and Japan's Ministry of Health, Labour and Welfare have previously granted Orphan Drug Designation to imsidolimab for the treatment of GPP. This marks the first time the European Commission has granted orphan designation recognition for a drug to treat GPP in the European Union (EU).

WASHINGTON, Aug. 22, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the NEREUS™ branded No. 47 entry from Rahal Letterman Lanigan Racing, driven by Mick Schumacher, is set to compete this weekend in the inaugural Freedom 250 Grand Prix of Washington, D.C.

PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.

Vanda Pharmaceuticals Inc. (VNDA) Q2 2026 Earnings Call Transcript